Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
How do you use P1NP in your clinical practice to guide management of osteoporosis?
Related Questions
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
What range of musculoskeletal complaints have you seen with romosozumab use?
Would you consider teriparatide use in a patient with prior radiation therapy, given that the black box warning regarding osteosarcoma risk has been removed by the FDA?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
Is there a PTH elevation above which you would be hesitant to use an anabolic agent in a patient with osteoporosis and CKD stage 4 or 5?
How do you reduce the risk of contralateral fracture in a patient with atypical femur fracture from prolonged bisphosphonate use?
Would you use PTH analog in a patient with severe osteoporosis (T score below - 3.5) who has been found to have idiopathic hypercalciuria with normal labs (PTH, vit D, Ca)?
When considering pharmacologic treatments recommended by the 2022 glucocorticoid induced osteoporosis guidelines, do you use NNT/NNH to select between each treatment option by risk categories (e.g., moderate, high, very high)?
What is your approach to managing osteoporosis in patients with end stage kidney disease?
